Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Forest to develop Adamas’ memantine/donepezil combo for Alzheimer’s

Executive Summary

Adamas Pharmaceuticals Inc. (optimized and controlled-release formulations of aminoadamantane compounds for CNS diseases) has licensed Forest Laboratories Inc. exclusive US development and marketing rights to its Phase III Arimenda, a fixed-dose, once-daily combination of extended-release memantine (which Forest sells as Namenda XR for moderate-to-severe Alzheimer’s disease) and immediate-release donepezil (Pfizer/Eisai’s Aricept) for moderate-to-severe dementia associated with Alzheimer’s.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies